To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva (NCT05090891)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
🩺 Plain-English Summary (8th-Grade Level)
This Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a clinical diagnosis of fibrodysplasia ossificans progressiva (FOP).
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Rochester — Rochester, Minnesota
Age range: 2 Years to 99 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (24 Sites)
- Mayo Clinic Rochester — Rochester, Minnesota
- Children'S Hospital of Philadelphia — Philadelphia, Pennsylvania
- Penn Medicine - Perelman Center For Advanced Medicine — Philadelphia, Pennsylvania
- Hospital Italiano de Buenos Aires — Buenos Aires,
- Royal North Shore Hospital — St Leonards, New South Wales
- Murdoch Children'S Research Institute — Parkville, Victoria
- Albert Einstein Israelite Hospital — São Paulo,
- University Health Network Toronto General Hospital — Toronto, Ontario
- Centro de Estudios Reumatologicos — Santiago,
- Beijing Childrens Hospital Capital Medical University — Beijing,
- Tongji Hospital of Tongji University — Shanghai,
- Shanghai Childrens Medical Center — Shanghai,
- Childrens Hospital of Fudan University — Shanghai,
- Ap-Hp Hopital Lariboisiere — Paris,
- Hopital Necker-Enfants Malades — Paris,
- Uniklinik Koln — Cologne,
- Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore — Rome,
- Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra — Tlalpan,
- Amsterdam Umc - Vu Medisch Centrum (Vumc) — Amsterdam,
- Starship Childrens Hospital — Auckland,
- Groote Schuur Hospital Radiation Oncology — Cape Town,
- Seoul National University Hospital — Seoul,
- Hospital Universitario Ramon Y Cajal — Madrid,
- Royal National Orthopaedic Hospital — Stanmore,
📞 Contact the Study Coordinator
Phone: (855) 463-3463
Email: medinfo@incyte.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Fibrodysplasia Ossificans Progressiva (FOP)
- The Fibrodysplasia Ossificans Progressiva (FOP) Registry — North Kansas City, Missouri
- IL1 Inhibition in FOP — San Francisco, California
Explore by condition: All Fibrodysplasia Ossificans Progressiva (FOP) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.